LRRC8A potentiates temozolomide sensitivity in glioma cells via activating mitochondria-dependent apoptotic pathway
Chloride (Cl−), a primary anion in the extracellular fluid, plays an important role in a variety of physiological and pathological processes, such as cell apoptosis and proliferation. However, the information about Cl− in cancer cell apoptosis and chemoresistance is poorly understood. In the present study, we found that temozolomide (TMZ) treatment led to a decrease in intracellular concentration of Cl− ([Cl−]i) in both U87 and TMZ-resistant U87/R glioma cells. The decrease in [Cl−]i was more noticeable in U87 cells than in U87/R cells. Moreover, the expression of LRRC8A was reduced in U87/R cells compared with U87 cells. LRRC8A downregulation inhibited TMZ, induced the decrease in [Cl−]i and abolished the difference of [Cl−]i between U87 cells and U87/R cells. Knockdown of LRRC8A using small interfering RNA attenuated TMZ-induced U87 cell growth inhibition and apoptosis, while overexpression of LRRC8A by adenoviral infection enhanced the effect of TMZ on U87 and U87/R cell viability and apoptosis. Furthermore, LRRC8A downregulation inhibited TMZ-induced mitochondria-dependent apoptosis, including elevated Bcl-2 expression, reduced Bax expression, cytochrome c release, and caspase nine and caspase three activation. On the contrary, upregulation of LRRC8A augmented the activation of mitochondria-dependent apoptotic pathway in U87 and U87/R cells. In conclusion, this study demonstrates that LRRC8A potentiates TMZ-induced glioma cell apoptosis via promoting mitochondria-dependent apoptosis, suggesting that LRRC8A can be represented as a novel target for drug resistance treatment in glioma cells.
KeywordsDrug resistance Glioma Chloride LRRC8A Mitochondrial apoptosis Temozolomide
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 4.Hombach-Klonisch S, Mehrpour M, Shojaei S, Harlos C, Pitz M, Hamai A, et al. Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response. Pharmacol Ther. 2018;184:13–41. https://doi.org/10.1016/j.pharmthera.2017.10.017.CrossRefGoogle Scholar
- 5.Koberle B, Tomicic MT, Usanova S, Kaina B. Cisplatin resistance: Preclinical findings and clinical implications. Bba-Rev Cancer. 2010;1806(2):172–82.Google Scholar
- 7.Hoffmann EK, Lambert IH. Ion channels and transporters in the development of drug resistance in cancer cells. Philos T R Soc B. 2014;369(1638).Google Scholar
- 17.Sorensen BH, Nielsen D, Thorsteinsdottir UA, Hoffmann EK, Lambert IH. Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation. Am J Physiol Cell Physiol. 2016;310(11):C857-73. https://doi.org/10.1152/ajpcell.00256.2015.CrossRefGoogle Scholar
- 21.Yang H, Huang LY, Zeng DY, Huang EW, Liang SJ, Tang YB, et al. Decrease of intracellular chloride concentration promotes endothelial cell inflammation by activating nuclear factor-kappaB pathway. Hypertension. 2012;60(5):1287–93. https://doi.org/10.1161/HYPERTENSIONAHA.112.198648.CrossRefGoogle Scholar